CH689327A5 - Pharmaceutical preparation for cancer treatment - Google Patents
Pharmaceutical preparation for cancer treatment Download PDFInfo
- Publication number
- CH689327A5 CH689327A5 CH00176/95A CH17695A CH689327A5 CH 689327 A5 CH689327 A5 CH 689327A5 CH 00176/95 A CH00176/95 A CH 00176/95A CH 17695 A CH17695 A CH 17695A CH 689327 A5 CH689327 A5 CH 689327A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cancer
- composition
- treatment
- active substances
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft ein pharmazeutisches Präparat für die Behandlung von Krebs bzw. Krebserkrankungen sowie ein Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung. The present invention relates to a pharmaceutical preparation for the treatment of cancer or cancer and a method for producing a pharmaceutical composition.
Die Behandlung von Krebs erfolgt in der Regel dadurch, dass die vom Krebs befallenen Zellen bzw. "bösartige Neubildungen" zerstört werden, sei dies beispielsweise mittels sogenannter Chemotherapie oder sogenannter Radiotherapie. Das grosse Problem bei den bekannten Therapien besteht darin, dass in der Regel auch gesunde bzw. normale Zellen zerstört werden, was zu schwerwiegenden Schädigungen führt. Cancer is usually treated by destroying the cancerous cells or "malignant neoplasms", for example by means of so-called chemotherapy or so-called radiotherapy. The big problem with the known therapies is that usually healthy or normal cells are also destroyed, which leads to serious damage.
Die Aufgabe der vorliegenden Erfindung besteht im Schaffen einer Methode bzw. eines pharmazeutischen Präparates, um einerseits die Bildung weiterer Krebszellen zu verhindern und andererseits, um bereits befallene Krebszellen zu neutralisieren bzw. abzutöten. The object of the present invention is to create a method or a pharmaceutical preparation, on the one hand, to prevent the formation of further cancer cells and, on the other hand, to neutralize or kill already infected cancer cells.
Erfindungsgemäss wird die gestellte Aufgabe mittels eines pharmazeutischen Präparates gemäss dem Wortlaut nach Anspruch 1 gelöst. According to the invention, the object is achieved by means of a pharmaceutical preparation according to the wording according to claim 1.
Vorgeschlagen wird eine Zusammensetzung für die Behandlung von Krebs bzw. von Krebserkrankungen, welche als mindestens eine der Wirksubstanzen Thymin und/oder Kynurenin enthält. A composition for the treatment of cancer or cancer diseases is proposed which contains thymine and / or kynurenine as at least one of the active substances.
Bei Patienten mit bösartigem Krebs (Neoplasien) wurden durch die Analyse der Einflüsse der wichtigsten Aminosäuren in der Zellbiologie bzw. bei der Zellbildung die besten Resultate erzielt. In patients with malignant cancer (neoplasia), the best results were obtained by analyzing the influences of the most important amino acids in cell biology and cell formation.
Die bösartige Krebszelle weist eine biochemische Schwäche während der Mitose (Intervall zwischen zwei Teilungsphasen) der Zelle auf. Die erfindungsgemäss vorgeschlagene Zusammensetzung weist als Grundlage eine doppelte Wirkung auf diese biochemische enzymatische Schwäche auf, nämlich: The malignant cancer cell has a biochemical weakness during mitosis (interval between two division phases) of the cell. The composition proposed according to the invention has a double effect on this biochemical enzymatic weakness, namely:
1. eine biochemische Reaktion der Zellen, sowie 2. eine Wirkung der Deoxyribonucleinsäure. 1. a biochemical reaction of the cells, as well 2. an effect of deoxyribonucleic acid.
Die biochemische Reaktion ist verantwortlich für die genetische Bildung von Oxy-Kynurenin-Formyl und die Wirkung der Deoxyribonucleinsäure für die genetische Bildung von Thymin. The biochemical reaction is responsible for the genetic formation of oxy-kynurenine formyl and the action of deoxyribonucleic acid for the genetic formation of thymine.
Die Zusammenführung von Thymin mit Kynurenin in einer wässrigen Kaliumhydroxid- oder Natriumhydroxid-Lösung ergibt in der Krebszelle eine doppelte Formylneutralisation und verhindert so den unkontrollierten mitotischen Prozess. Eine Krebszelle wird in eine amitotische Zelle verwandelt. Combining thymine with kynurenine in an aqueous potassium hydroxide or sodium hydroxide solution results in a double formyl neutralization in the cancer cell and thus prevents the uncontrolled mitotic process. A cancer cell is transformed into an amitotic cell.
Die Rückbildung der Tumormasse wurde "in Vivo" bei Versuchstieren und auch bei Patienten durch die Einnahme des erfindungsgemäss vorgeschlagenen, pharmazeutischen Präparates beobachtet, besonders gut reagierten dabei Patienten, die weder einer Chemo- noch einer Radiotherapie unterzogen worden sind. Bei allen behandelten Fällen von neoplasischen Tumoren wurde eine Fibrosis aus der Tumormasse im Verlauf von ca. 180 Tagen gebildet. The regression of the tumor mass was observed "in vivo" in experimental animals and also in patients by taking the pharmaceutical preparation proposed according to the invention, and patients who had neither chemotherapy nor radiotherapy reacted particularly well. In all treated cases of neoplastic tumors, fibrosis was formed from the tumor mass over the course of approximately 180 days.
Zur Behandlung für vom Krebs befallene Patienten wird beispielsweise ein pharmazeutisches Präparat verwendet, mit der nachfolgenden Rezeptur: 3 g Thymin 3,3 g Kynurenin die beiden Substanzen werden in 50 ml Wasser, beinhaltend 0,63 g Kalimhydroxid bzw. Natriumhydroxid, gelöst. For the treatment of cancer patients, for example, a pharmaceutical preparation is used, with the following formula: 3 g thymine 3.3 g kynurenine the two substances are contained in 50 ml of water 0.63 g of potassium hydroxide or sodium hydroxide, dissolved.
Anstelle vom teuren Kynurenin kann auch Tryptophan verwendet werden. Tryptophan can also be used instead of the expensive kynurenine.
Die tägliche Dosis für die Behandlung von Krebspatienten beträgt 3 x am Tage ca. 20-40 Tropfen des pharmazeutischen Präparates, wobei jeweils die einzunehmende Dosis in gesüsstem Wasser verdünnt werden kann. The daily dose for the treatment of cancer patients is approx. 20-40 drops of the pharmaceutical preparation 3 times a day, whereby the dose to be taken can be diluted in sweetened water.
Bei der angegebenen Rezeptur handelt es sich selbstverständlich nur um ein Beispiel, wesentlich im pharmazeutischen Präparat ist die Verwendung der angegebenen Wirksubstanzen, welche in einer wässrigen Kaliumhydroxid- oder Natriumhydroxid-Lösung gelöst sind. The recipe given is, of course, only an example; what is essential in the pharmaceutical preparation is the use of the active ingredients stated, which are dissolved in an aqueous potassium hydroxide or sodium hydroxide solution.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00176/95A CH689327A5 (en) | 1995-01-23 | 1995-01-23 | Pharmaceutical preparation for cancer treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00176/95A CH689327A5 (en) | 1995-01-23 | 1995-01-23 | Pharmaceutical preparation for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CH689327A5 true CH689327A5 (en) | 1999-02-26 |
Family
ID=4181000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH00176/95A CH689327A5 (en) | 1995-01-23 | 1995-01-23 | Pharmaceutical preparation for cancer treatment |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH689327A5 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047571A2 (en) * | 2001-11-28 | 2003-06-12 | Metagen Pharmaceuticals Gmbh | Use of a kmo inhibitor for producing a pharmaceutical composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO89432A2 (en) * | 1984-07-12 | 1986-06-30 | Spitalul Clinic De Urgenta,Ro | DRUG COMPOSITION FOR THE TREATMENT OF CANCER |
WO1993015738A1 (en) * | 1992-02-12 | 1993-08-19 | Urban Waldthaler | Medicament for the treatment and/or prophylaxis of folate metabolism disorders |
-
1995
- 1995-01-23 CH CH00176/95A patent/CH689327A5/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO89432A2 (en) * | 1984-07-12 | 1986-06-30 | Spitalul Clinic De Urgenta,Ro | DRUG COMPOSITION FOR THE TREATMENT OF CANCER |
WO1993015738A1 (en) * | 1992-02-12 | 1993-08-19 | Urban Waldthaler | Medicament for the treatment and/or prophylaxis of folate metabolism disorders |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 198703, Derwent World Patents Index; AN 1987-019866 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047571A2 (en) * | 2001-11-28 | 2003-06-12 | Metagen Pharmaceuticals Gmbh | Use of a kmo inhibitor for producing a pharmaceutical composition |
WO2003047571A3 (en) * | 2001-11-28 | 2003-10-02 | Metagen Pharmaceuticals Gmbh | Use of a kmo inhibitor for producing a pharmaceutical composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60032543T2 (en) | Topically administrable zinc compositions | |
DE2832204A1 (en) | AGENTS FOR THE TREATMENT OF NERVOUS DISEASES, METHOD OF ITS MANUFACTURING AND ITS USES | |
EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
EP0236951A2 (en) | Use of diphenyl hydantoin and its derivatives in the preparation of a pharmaceutical agent for the treatment of immune diseases | |
EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
EP0439640B1 (en) | Method for preparing agents for the therapy of skin diseases | |
DE1695976B2 (en) | 4-Hydroxy-l- ß -D-ribofuranosyl-tetrahydro-2 (1H) -pyrimidinone, process for its preparation and its use | |
DE3726945A1 (en) | L-Carnitine derivatives of valproic acid and pharmaceuticals containing these | |
EP1056467A2 (en) | Method for the treatment of diseases or disorders of the inner ear | |
DE4006564C2 (en) | Use of hexadecylphosphocholine in the treatment of psoriasis | |
DE2951050A1 (en) | MEDICINES FOR TREATING TUMORS AND CANCER DISEASES AND METHOD FOR THE PRODUCTION THEREOF | |
EP0245669A2 (en) | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs | |
DE60216292T2 (en) | CALCIUM TRIFLUORACETATE WITH CYTOTOXIC EFFECT | |
CH689327A5 (en) | Pharmaceutical preparation for cancer treatment | |
EP0403575B1 (en) | Acyl carnitine for the treatment and prevention of virus infections | |
EP1156811B1 (en) | Copper agonist that binds on the copper binding site of amyloid precursor protein (app) and/or exerts an inhibiting effect on the release of amyloid-beta-peptide | |
DE19738484C2 (en) | Use of N-propanoyl-mannosamine as a medication | |
WO2004054497A2 (en) | Use of a trpm8-activating substance for the treatment of tumours | |
DE3048154C2 (en) | ||
CH634546A5 (en) | METHOD FOR PRODUCING COMPLEX COMPOUNDS OF AMINODICARBONIC ACIDS WITH MAGNESIUM AND HALOGENS. | |
DE10238161A1 (en) | Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule | |
DE2916880C2 (en) | Medicines with sedative and sleep-inducing effects | |
EP0858465B1 (en) | Anti-tumoral protein | |
DE3129714A1 (en) | ANTI-PSYCHOTIC | |
DE2245826C3 (en) | Salts of N-cyano-ethyl-N'-m-chlorophenyl-piperazine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCOW | Change of address of patent owner(s) |
Free format text: MARIA MAGDALENA HUBER;HOECHHUSMATT 15;6130 WILLISAU (CH) $ PAUL HUBER;C/O MARIA MAGDALENA HUBER HOECHHUSMATT 15;6130 WILLISAU (CH) |
|
PUEA | Assignment of the share |
Owner name: PAUL HUBER Free format text: JOSEF WALLER#GALLUS-STEIGER-STRASSE#6233 BUERON (CH) $ PAUL HUBER#C/O J. WALLER GALLUS-STEIGER-STRASSE#6233 BUERON (CH) -TRANSFER TO- PAUL HUBER#C/O J. WALLER GALLUS-STEIGER-STRASSE#6233 BUERON (CH) $ MARIA MAGDALENA HUBER#HOECHHUSMATT 15#6130 WILLISAU (CH) |
|
PL | Patent ceased |